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Rapid replacement by non-
vaccine pneumococcal serotypes 
may mitigate the impact of the 
pneumococcal conjugate vaccine on 
nasopharyngeal bacterial ecology
Brenda Kwambana-Adams1,3, Blake Hanson2, Archibald Worwui1, Schadrac Agbla1,3, 
Ebenezer Foster-Nyarko1, Fatima Ceesay1, Chinelo Ebruke1,3, Uzochukwu Egere1, Yanjiao 
Zhou2, Maze Ndukum4, Erica Sodergren2, Michael Barer5, Richard Adegbola6, George 
Weinstock2 & Martin Antonio1,3,7
There is growing concern that interventions that alter microbial ecology can adversely affect health. We 
characterised the impact of the seven-valent pneumococcal conjugate vaccine (PCV7) on pneumococcal 
carriage and the bacterial component of the nasopharyngeal microbiome during infancy. Newborns 
were recruited into three groups as follows: Group1 (n = 33) was the control group and comprised 
infants who received PCV7 after 6 months and came from unvaccinated communities. Group 2 (n = 30) 
came from unvaccinated communities and Group 3 (n = 39) came from vaccinated communities. 
Both group 2 and 3 received PCV7 at 2, 3 and 4 months. Culture and 16 S rRNA gene sequencing were 
performed on nasopharyngeal specimens collected at regular intervals from infants. Nasopharyngeal 
carriage of PCV7 serotypes in Group 1 was significantly higher than in Group 2 and 3 (p < 0.01). 
However, pneumococcal carriage remained comparable due to an expansion of non-vaccine serotypes 
in Groups 2 and 3. Determination of phylogenetic dis(similarities) showed that the bacterial community 
structures were comparable across groups. A mixed effects model showed no difference in community 
richness (p = 0.15) and Shannon α-diversity (p = 0.48) across the groups. Immediate replacement of 
pneumococcal vaccine serotypes with non-vaccine serotypes may mitigate the impact of PCV7 on 
nasopharyngeal bacterial community structure and ecology.
Streptococcus pneumoniae, the pneumococcus, causes several serious and often life-threatening infections includ-
ing meningitis, pneumonia and bacteraemia1. The 7-valent pneumococcal polysaccharide-diphtheria CRM197 
protein conjugate vaccine (PCV7) was licensed in 2000 and markedly reduced the carriage of vaccine serotypes2, 3  
and the incidence of invasive disease4–6. Childhood deaths attributed to pneumococcus reduced from 735,000 in 
2000 to 476,000 in 2008 following widespread use of PCVs. The 10-valent PCV formulation (PCV10) includes 
all the serotypes in PCV7 and serotypes 1, 5 and 7F7, 8. The 13-valent PCV (PCV13) formulation includes all the 
additional serotypes 3, 6A and 19A. PCV10 and PCV13 have replaced PCV7 and had been introduced in 132 
countries globally as of September 20167.
Although PCVs are a remarkable public health success, their long-term utility is threatened by the emer-
gence of serotype replacement and possibly species replacement. Although serotype replacement9, 10 and serotype 
switching11–13 associated with widespread use of PCVs have been reported, the impact of vaccination on the 
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nasopharyngeal microbial ecology, which may influence replacement disease, has not been determined among 
West African children. Few studies have reported changes in the epidemiology of bacterial diseases associated 
with widespread use of PCV714–16; however, it is unclear how these changes are related to nasopharyngeal micro-
bial colonisation. The nasopharynx is an important reservoir of commensal and pathogenic microbes, which can 
migrate to the sinuses, middle ear and lower respiratory tract and invade the blood system. The issue of replace-
ment in carriage and disease is of particular interest within the Gambian context where infant pneumococcal 
nasopharyngeal carriage rates exceed 90% and PCV7 protects against approximately 63% of previously circulating 
serotypes17, 18. PCV7 was introduced in the routine immunization programme in The Gambia in August 2009, 
and was replaced by PCV13 in June 2011.
We set out to determine the effects of PCV7 on nasopharyngeal microbial ecology and assess its wider pub-
lic health impact by asking whether vaccination significantly alters the composition and structure of the infant 
nasopharyngeal microbiome. A birth cohort of 102 Gambian newborns recruited into three groups with distinct 
PCV7 vaccine exposures was rigorously sampled for one year to address this question.
Results
Characteristics of study participants. All newborns from participating villages for whom informed 
parental consent was obtained were recruited into the study until each of the vaccination groups had at least 30 
children. A total of 102 children were recruited into each of the study groups as follows, Group 1 (n = 33), Group 
2(n = 30) and Group 3 (n = 39). The baseline characteristics of the newborns recruited into in each of the study 
groups are summarised in Table 1. There were no significant differences in the baseline characteristics across the 
study groups except for birthplace, maternal vaccination and sibling vaccination status. Group 3 newborns came 
from villages with widespread PCV7 vaccination and were expected to have high rates of maternal and sibling 
vaccination. The study completion rate was 94% (96/102); 6 children did not complete the study, 3 died and 3 
dropped out or were lost to follow-up. None of the children that died had been vaccinated with PCV7. 1595 naso-
pharyngeal swabs were collected from the children, with a mean of 16 specimens (range 1 to 17) per infant over 
the 12 months of follow-up as outlined in Fig. 1.
Pneumococcal carriage dynamics. Pneumococcus was found in 79% (1258/1595) of the nasopharyngeal 
specimens by culture. Vaccine serotypes were detected in 30% (383/1258) of the pneumococcus positive speci-
mens by the sweep latex agglutination serotyping method19. Pneumococcal carriage among Group 1 infants in the 
first 12 months of life was 79%(95CI: 76–83), comparable to Group 2 75%(95% CI: 71–79), p = 0.28 and Group 3 
82%(95% CI: 79–85), p = 0.29. In contrast, carriage of PCV7 serotypes was 37% (95% CI: 32–41) among Group 
1 infants, significantly higher than among Group 2 infants 20% (95% CI: 17–24%), p < 0.01 and Group 3 infants 
17% (95CI: 14–20), p < 0.01. Pneumococcal, vaccine type and non-vaccine type carriage across the 12 months 
of follow-up are shown in Fig. 2A,B and C. The carriage of vaccine type pneumococci decreased by nearly half 
Characteristics Category
Group 1 
(n = 33)
Group 2 
(n = 30)
Group 3 
(n = 39) p-value
Sex, n (%)
Male 20 (60.6) 13 (43.3) 19 (48.7)
0.37a
Female 13 (39.4) 17 (56.7) 20 (51.3)
Birthplace, n (%)
Home 9 (27.3) 20 (66.7) 23 (59.0)
<0.01bHealth Centre 4 (12.1) 2 (6.7) 10 (25.6)
Hospital 20 (60.6) 8 (26.7) 6 (15.4)
Birth type, n (%) Vaginal 33 (100) 30 (100) 39 (100) N/A
Mother’s age in years, n (%)
<20 3 (9.1) 2 (6.7) 6 (15.4)
0.84b20–34 20 (60.6) 20 (66.7) 23 (59.0)
≥35 10 (30.3) 8 (26.7) 10 (25.6)
Gestation, n (%)
Full term 33 (100) 30 (100) 38 (97.4)
0.99b
Premature 0 (0.0) 0 (0.0) 1 (2.6)
Siblings, n (%)
0 4 (12.1) 4 (13.3) 6 (15.4)
0.75b1–3 16 (48.5) 12 (40.0) 21 (53.9)
>3 13 (39.4) 14 (46.7) 12 (30.8)
Ethnicity, n (%)
Mandinka 6 (18.2) 7 (23.3) 12 (30.8)
0.38aJola 18 (54.6) 18 (60.0) 23 (59.0)
Other 9 (27.3) 5 (16.7) 4 (10.3)
Birth weight in kg* Median (min, max) 3.1 (2.5–3.9) 3 (2.6–3.4) 3 (1.9–4.3) 0.34c
Mother vaccinated, n (%)
No 33 (100) 30 (100) 18 (46.2)
<0.01a
Yes 0 (0.0) 0 (0.0) 21 (53.8)
Vaccinated siblings, n (%)
No 33 (100) 30 (100) 34 (87.2)
0.01b
Yes 0 (0.0) 0 (0.0) 5 (12.8)
Table 1. Baseline characteristics of newborns and their mothers by study group. aChi square test. bFisher’s 
exact test. cKruskal-Wallis test. *Birth weight was not recorded for 15, 16 and 11 of Group 1, 2 and 3 newborns 
respectively.
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following the first dose of PCV7 given at 9 weeks among Group 2 infants (Fig. 2B). Vaccine type carriage declined 
between 35 and 52 weeks among Group 1 infants following the nationwide introduction of PCV7. Although 
pneumococcal acquisition was similar across all three groups (Fig. 2D), Group 1 infants acquired vaccine type 
pneumococci more rapidly than Group 3 infants (Fig. 2E). The most common non-vaccine serotypes across all 
the vaccination groups were 19A, 23B and 35B. Carriage of serotype 15B was most common among Group 3 
infants who came from heavily vaccinated villages and received PCV at 2, 3 and 4 months (Fig. 2G).
Carriage of pneumococcus among children born to vaccinated mothers was 78% (95% CI: 76–81%), compa-
rable to carriage rates among infants born to unvaccinated mothers 83% (95% CI: 78–87%), p < 0.065. However, 
infants with vaccinated mothers had significantly lower carriage of pneumococcal vaccine serotypes, 19%(95% 
CI:14–23%) compared to infants with unvaccinated mothers 25%(95% CI: 23–28%), p = 0.014. Nonetheless, 
there was no significant difference in carriage of vaccine serotypes among children with at least one vaccinated 
sibling 23%(95% CI: 14–32%), and those without any vaccinated siblings 24%(95% CI: 22–26%), p = 920.920. 
Infants born at a health facility (health center or hospital) had significantly higher carriage of pneumococcal vac-
cine serotypes 27%(95% CI: 23–30%) than infants born at home 21%(95% CI: 19–24%), p = 0.009. There was no 
difference in the carriage of pneumococcus among children born at health facilities 79%(95% CI: 76–82%) and at 
home 79%(95% CI: 77–82%), p = 0.862.
Nasopharyngeal microbial communities. Of the 1595 nasopharyngeal specimens collected, 16S rDNA 
deep sequencing was successfully performed on 91% (1460/1595). Initial amplification and/or sequencing with 
a minimum of 500 reads per sample failed in 9% of (135/1595) NPS specimens. The sequences from this data-
set were binned into 814 operational taxonomic units (OTUs) representing at least 297 genera and 15 Phyla. 
Firmicutes, Proteobacteria, Bacteroidetes and Actinobacteria accounted for at least 90% of the nasopharyngeal 
microbiota across all time points in each of the groups (Fig. 3A). Likewise, the top ten genera, which included 
Streptococcus, Staphylococcus, Corynebacterium, Pseudomonas, Moraxella and Haemophilus, accounted for more 
than 70% of the microbiota throughout the first 12 months of life (Fig. 3B). These microbes form the backbone of 
the infant nasopharyngeal microbiome while there are numerous low abundance microbes, which may account 
for most of the diversity within and across individuals.
In the first week of life, Staphylococcus, Corynebacterium and Streptococcus were the dominant genera 
(Fig. 3B). However, while the initial dominance of Staphylococcus decreased in the subsequent weeks, the relative 
abundance of Streptococcus and Pseudomonas increased, accounting for over 50% of the microbiota at some visits.
Figure 1. Flowchart of infant recruitment and sample collection.
www.nature.com/scientificreports/
4SCIenTIFIC REPORts | 7: 8127  | DOI:10.1038/s41598-017-08717-0
Effect of vaccination on community composition and structure. To evaluate the effect of PCV7 
vaccination on overall microbial composition, the phylogenetic dis(similarities) among communities from the 
three groups were evaluated by MDS/PCoA on weighted-UniFrac distance. There were no distinct shifts in com-
munity composition associated with vaccination group as communities from all three groups clustered closely 
together at each of the 17 age-based visits (Fig. 4). The distribution of the most abundant OTUs across time 
among the groups appeared very similar at both Phylum and Genus taxonomic levels (Fig. 3). MDS/PCoA on 
weighted-UniFrac suggested higher variability in community composition between the 15th and 27th weeks after 
birth compared to the early and latter weeks (Fig. 4).
A random intercept mixed-effects model was used to investigate the interaction between richness 
(Supplementary Table 1) and Shannon α-diversity (Supplementary Table 2) with vaccination group and age 
adjusting for time-variant and time-invariant explanatory variables. The square root of richness was higher 
between 11 and 17 weeks after birth (adjusted difference: 0.75 (95% CI: 0.41, 1.10) and between 19 and 27 weeks 
after birth (adjusted difference: 0.82 (95% CI: 0.30, 1.34) compared to the first 9 weeks of life. No difference in 
richness was found between the first 9 weeks of life and the last 20 weeks of the first year. These trends are vis-
ualized in Fig. 5A. Nasopharyngeal microbial communities harboured a median of 67 (range 1–264) OTUs per 
specimen and the distribution of richness was similar across all three groups (Fig. 5B). Shannon α-diversity 
decreased over time during the first 9 weeks of life (adjusted time effect: −0.06 (95% CI: −0.08, −0.03)) and 
became steady thereafter (visualized in Fig. 5C). The distribution of Shannon α-diversity was similar across all 
three groups (Fig. 5D). There was no evidence of difference in richness (p = 0.15) and Shannon α-diversity across 
the three vaccination groups (p = 0.48) in the mixed effects random intercept model. Other factors such as breast-
feeding and mother’s age appeared to have significant associations with both richness and Shannon α-diversity 
(Supplementary Tables 1 and 2).
Effect of PCV7 vaccination on individual OTUs. Differential abundance of individual OTUs across the 
vaccination groups was evaluated by the use of the negative binomial distribution and shrinkage estimator for the 
distribution’s variance. The variance of most OTUs across all the nasopharyngeal samples was very low (<log10 
(−4) as shown in Fig. 6. There were 38, 27, and 33 OTUs that had differential abundance between groups 1 & 
Figure 2. Nasopharyngeal carriage dynamics of pneumococcus, vaccine and non-vaccine serotypes in the first 
year of life. Carriage rates of pneumococcus (A), vaccine (B) and non-vaccine serotypes (C). Kaplan Meier 
Survival Curve for time to first acquisition of pneumococcus (D), vaccine serotypes (E) and non-vaccine 
serotypes (F). Distribution of the top ten vaccine serotypes by group (G). The vertical dashed lines are the study 
2, 3, and 4 month vaccination time points. P values generated from an adjusted logistic regression model. The 
line colour denotes the group: red for Group 1, green for group 2 and blue for Group 3.
www.nature.com/scientificreports/
5SCIenTIFIC REPORts | 7: 8127  | DOI:10.1038/s41598-017-08717-0
2, groups 1 & 3 and groups 2 & 3 respectively (Fig. 6A,B and C). The OTUs with differential abundance across 
all the groups represented 56 unique OTUs belonging to the Firmicutes, Proteobacteria and Actinobacteria 
phyla. A total of 9 OTUs representing Streptococcus, Moraxella, Dolosigranulum, Haemophilus, Pseudomonas 
and Pelomonas genera had significantly different abundance across the vaccination groups after controlling for 
confounders in a mixed effect model performed as described above (Table 2). Group 2 and Group 3 infants had 
reduced abundance of 7 of the 9 OTUs compared to Group 1 infants.
Discussion
There is growing concern that vaccination and antimicrobial treatment strategies that alter the normal balance 
of microbial communities could have temporal or pervasive adverse effects on health20. In this unique study of 
infants followed up from birth to 1 year with intensive sampling, we have demonstrated that while PCV7 vacci-
nation effectively reduces the nasopharyngeal carriage of vaccine serotypes, pneumococcal carriage remains high 
(above 75%) among vaccinated infants due to an immediate expansion of non-vaccine serotypes throughout the 
first year of life. We have concurrently shown that the overall nasopharyngeal microbial community composi-
tion and structure remain largely unaltered by exposure to PCV7, even in the presence of herd immunity. These 
findings together suggest that exposure to PCV7 does not significantly alter the structure and composition of the 
infant nasopharyngeal microbiome among Gambian infants, likely due to immediate replacement of vaccine by 
non-vaccine serotypes.
Replacement of vaccine with non-vaccine serotypes associated with PCVs was reported even before the vac-
cine was first licensed. Following a small study of an experimental pentavelent CRM197 PCV among children, 
Obaro and colleagues reported a reduction in the carriage of vaccine types, which was countered by a com-
mensurate increase in the carriage of non-vaccine serotypes21. Virtually complete replacement of vaccine with 
non-vaccine serotypes in carriage associated with PCV vaccination has been reported in several randomized 
controlled trials in South Africa22, the Netherlands23, Israel24, the United States of America25 and subsequently 
in The Gambia26. A new insight this study adds is how rapidly this replacement takes place among infants. 
Nasopharyngeal swabs were collected every two weeks which provided a unique opportunity to show that not 
only does clearance of vaccine serotypes occur rapidly (<14 days) following the first dose of PCV7 but serotype 
replacement also occurs concurrently (Fig. 2). This is in contrast to a previous report that suggested that reduc-
tions in vaccine-serotype carriage occur within one or two months27.
Figure 3. Composition of the nasopharyngeal microbiome in the first year of life. The distribution of the 
top 5 phyla (A) and the top 10 genera (B) in the nasopharyngeal microbiome from birth to 52 weeks for each 
vaccination group is shown.
www.nature.com/scientificreports/
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Figure 4. Clustering of nasopharyngeal microbial profiles by group in the first year of life. The phylogenetic 
dis(similarities) among communities from the three vaccination groups were evaluated by MDS/PCoA on 
weighted-UniFrac distances. The dotted eclipses show the 95% confidence intervals for the ordinations for 
each group at each time point. Each circle represents the microbial profile of a nasopharyngeal specimen from 
an infant and the colour denotes the vaccination group; red for Group 1, green for group 2 and blue for Group 
3. The distance between circles indicates the variability between nasopharyngeal microbial profiles i.e. longer 
distances show greater dissimilarity.
Figure 5. Nasopharyngeal microbiome richness and Shannon α-diversity in the first year of life by group. 
Richness over time (A); Density plot of richness (B); Shannon α-diversity in the first year of life (C); Shannon 
α-diversity in the first year of life (D). The vertical dashed lines are the study vaccination time points. The colour 
denotes the vaccination group; red for Group 1, green for group 2 and blue for Group.
www.nature.com/scientificreports/
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The most common non-vaccine serotypes carried by vaccinated children were serotypes19A, 35B and 15B. 
Increases in carriage of these serotypes following PCV vaccination have been widely reported across the globe 
and previously reviewed9. Previous pneumococcal surveys conducted in the same region as this study show that 
all three serotypes were circulating in the population prior to widespread use of PCV7 in the Gambia17, 28, 29. A 
pre-PCV longitudinal study of pneumococcal carriage among Gambian infants showed that serotype 35B was 
amongst the most commonly isolated serotypes at first acquisition and was amongst the predominant serotypes, 
accounting for just below 4% of pneumococcal isolates17. Both unmasking and increased acquisition are the 
most probable drivers of the expansion of the non-vaccine serotypes following PCV7 vaccination30. The detec-
tion of multiple serotypes was enhanced by the use of the sweep method as opposed to the traditional method 
in which one or two colonies per specimen are picked for serotyping. However, it is important to note that the 
culture-based detection of pneumococci employed in this study has lower sensitivity than molecular methods31, 32. 
Molecular pneumococcal detection and serotyping tools have the added benefit of enhancing multiple serotype 
detection and providing quantitative data19, 32, 33.
Rapid replacement of vaccine with non-vaccine serotype pneumococci is likely to have important implications 
for invasive disease. Population-based surveillance in the Upper River Region of The Gambia conducted between 
May 2008 and December 2014 showed a 47% increase in non-vaccine-type invasive pneumococcal disease, which 
was coupled with a significant decline in vaccine-type invasive pneumococcal disease following the introduction 
of PCV7 and PCV134. Interestingly, serotypes 19A and 35B were amongst the leading non-PCV7 serotypes caus-
ing invasive pneumococcal disease in The Gambia after the introduction of PCV7. It was also striking that 19A 
invasive pneumococcal disease persisted between 2013 and 2014 among children less than 5 years old despite 
widespread use of PCV13 in the country4.
At least one other study has investigated the impact of PCV7 on the nasopharyngeal microbiome. Biesbroek 
and colleagues investigated the impact of PCV7 vaccination on the nasopharyngeal microbiota among 97 vac-
cinated infants and 103 unvaccinated infants in the Netherlands34. The vaccinated infants received 3 doses of 
PCV7 at 2, 4 and 11 months of age. Deep sequencing of nasopharyngeal specimens collected at 12 and 24 months 
showed changes in the composition and diversity of the microbial communities associated with PCV7 vacci-
nation. However, these changes were temporary. Of note were the increases in the abundance of Veillonella, 
Prevotella, Fusobacterium, Streptococcus and Neisseria observed at 12 months. In this study, we found at least 
56 OTUs from the Firmicutes, Proteobacteria and Actinobacteria phyla that were differentially abundant across 
the vaccination groups. This included members of the Streptococcus, Staphylococcus and Moraxella species. After 
adjusting for possible confounders such as age, sex, season, birthplace, antibiotic treatment, travel history and 
Figure 6. Differentially abundant OTUs across vaccination group in the first year of life. Differential abundance 
of individual OTUs across the vaccination groups was evaluated by the use of the negative binomial distribution 
and shrinkage estimator for the distribution’s variance using the DESeq. 2 extension in the Phyloseq package 
in R. OTUs that were differentially abundant (alpha <0.01) between Group 1 and 2 (A), Group 1 and 3 (B), 
and Group 2 and 3 (C). The log10 variance of most OTUs across the samples was very low (D). The colours 
represent the phylum to which the OTUs belong: purple circles represent Firmicutes, green circles represent 
Proteobacteria and yellow circles represent Actinobacteria. The asterisk (*) indicates a taxanomic Class while the 
other labels represent Genera.
www.nature.com/scientificreports/
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malnutrition, only 9 OTUs had differential abundance across the vaccination groups (Table 2). Despite these dif-
ferences, the overall microbiome structure and composition were indistinguishable across the vaccination groups 
throughout the first year of life. This is consistent with findings from a small study conducted among 60 chil-
dren aged 12–59 months in Kenya in which the 10-valent pneumococcal non-typeable Haemophilus influenzae 
protein-D conjugate vaccine (PHiD-CV) was not found to significantly alter the nasopharyngeal microbiome35.
Although a few studies have reported changes in the carriage of other pathogens such as Staphylococcus aureus 
and Haemophilus influenzae that co-colonise the nasopharynx following PCV vaccination36–38, it is not clear if 
there is a link with nasopharyngeal carriage dynamics. However, this does not rule out the possibility that local-
ised changes in microbial ecology at the sites of infection, such as the middle ear in AOM, may play an important 
role39–43. It may be of some interest that the three OTUs that had significantly higher abundance among infants 
who received PCV7 and came from heavily vaccinated communities belonged to the Haemophilus, Moraxella and 
Streptococcus genera. This may warrant further investigation.
A key strength of this study is that the infants were intensively sampled in the first 6 months and followed 
up at regular intervals up to one year. A trade-off to the regular sampling was that the total number of infants 
recruited was only 102. Hence, more subtle changes in the nasopharyngeal microbiome composition and struc-
ture could have been missed. Group 1 was the control (unvaccinated) group in the initial study design, however, 
infants recruited into this group received PCV7 once it was introduced in The Gambia in August 2009. PCV7 was 
replaced by PCV13 in 2011 in The Gambia and it is unclear if the higher valency formulations will have similar 
impact on the nasopharyngeal microbiome.
The evidence presented here strongly suggests that as vaccine serotypes are cleared from the nasopharyngeal 
ecological niche, they are rapidly replaced by non-vaccine pneumococcal serotypes and not other bacterial spe-
cies. Although this may provide some reassurance, diligent surveillance of nasopharyngeal carriage is crucial to 
ensure that the net public health gains of PCVs are maintained over the long term.
Materials/Subjects and Methods
Ethical permission. Ethical approval to conduct this prospective longitudinal study was granted by the 
Gambian Government and Medical Research Council Unit The Gambia Joint Ethics Committee. Written, 
OTU
Taxanomic classification 
(Phylum; Class; Order; Family; 
Genus Group Frequency(%) (95% CI)
Mean Abundance% 
(Range) Coef. (95% Cl) P-value
169
Proteobacteria; 
Gammaproteobacteria; 
Pseudomonadales; 
Pseudomonadaceae, Pseudomonas
1 43 (39–48) 0.41 (0–24.78) 0.00 —
2 18 (15–22) 0.01 (0–0.55) −0.77 (−1.34–−0.21) 0.01
3 30 (26–34) 0.02 (0–0.43) −1.01 (−1.51–−0.51) 0.00
2 Firmicutes; Bacilli; Lactobacillales; Streptococcaceae, Streptococcus
1 99 (98–100) 29.74 (0–100) 0.00
2 99 (98–100) 32.09 (0–95.74) 0.14 (−0.15–0.42) 0.35
3 99 (98–100) 35.82 (0–100) 0.46 (0.19–0.74) <0.01
203 Firmicutes; Bacilli; Lactobacillales; Streptococcaceae; Streptococcus
1 46 (42–51) 0.21 (0–3.25) 0.00 —
2 25 (21–29) 0.01 (0–0.32) −0.71 (−1.32–−0.11) 0.02
3 37 (33–41) 0.02 (0–0.97) −0.78 (−1.35–−0.21) 0.01
205
Proteobacteria; 
Gammaproteobacteria; 
Pseudomonadales; Moraxellaceae; 
Moraxella
1 4 (35–44) 0.46 (0–40.47) 0.00 —
2 27 (23–31) 0.07 (0–3.36) −0.36 (−1.07–0.35) 0.32
3 33 (29–37) 0.03 (0–2.34) −0.95 (−1.6–−0.3) <0.01
3
Proteobacteria; 
Gammaproteobacteria; 
Pseudomonadales; Moraxellaceae; 
Moraxella
1 91 (88–93) 6.32 (0–69.94) 0.00 —
2 86 (83–89) 5.49 (0–72.88) 0.21(−0.18–0.61) 0.29
3 94 (92–96) 7.32 (0–79.12) 0.57 (0.19–0.95) <0.01
46
Firmicutes; Bacilli; Lactobacillales; 
Carnobacteriaceae; 
Dolosigranulum
1 73 (69–78) 1.65 (0–26.37) 0.00 —
2 62 (57–67) 0.42 (0–9.78) −1.02 (−1.67–−0.38) <0.01
3 74 (7–77) 0.84 (0–21.34) −0.94 (−1.55–−0.33) <0.01
48
Proteobacteria; Betaproteobacteria; 
Burkholderiales; 
Comamonadaceae; Pelomonas
1 34 (29–38) 0.18 (0–6.89) 0.00 —
2 23 (19–27) 0.09 (0–18.01) −0.54(−1.08–0.01) 0.05
3 34 (31–38) 0.1 (0–3.16) −0.58 (−1.08–−0.08) 0.02
8
Proteobacteria; 
Gammaproteobacteria; 
Pasteurellales; Pasteurellaceae; 
Haemophilus
1 77 (73–81) 4.44 (0–86.33) 0.00 —
2 74 (7–78) 4.4 (0–74.06) 0.66 (0.19–1.12) 0.01
3 85 (82–88) 5.74 (0–80.8) 0.64 (0.19–1.08) 0.01
89
Proteobacteria; 
Gammaproteobacteria; 
Pasteurellales; Pasteurellaceae; 
Haemophilus
1 33 (29–37) 0.45 (0–23.73) 0 —
2 26 (22–3) 0.03 (0–1.37) −0.27 (−0.91–0.38) 42
3 25 (22–29) 0.02 (0–0.92) −0.85 (−1.47–−0.23) 0.01
Table 2. OTUs with differential abundance by vaccination group in the first year of life. The mixed effect 
random intercept model was adjusted for time-invariant explanatory variables (gender, place of birth, number 
of siblings, maternal age) and time-variant explanatory explanatoryy (time, vaccination period, season, breast 
feeding, travelling, antibiotic usage and nutritional status based on weight for height).
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informed consent was obtained from the participants’ parents or guardian at recruitment. Enrolment of partici-
pants and all procedures were conducted in accordance with the relevant regulations and guidelines.
Study population. The Western Region is representative of rural areas in The Gambia. HIV prevalence is esti-
mated at 2% and the majority of villagers belong to the Jola, Mandinka and Fula ethnic groups29. Villages in the 
Western Region, The Gambia covering an area of approximately 90 km2 were selected for this study. Study partici-
pants were recruited from 27 villages each with estimated birth rates between three and twenty-six per year. The vil-
lages were split into 3 groups of 9 villages with estimated population sizes of 2000 and birth rates of approximately 80 
per year. Trained village reporters in each village recorded and reported pregnancies, births, deaths and other serious 
events. Recruitment of subjects was carried out between November 2008 and April 2009 after written informed con-
sent. To avert recruitment bias, all newborns from participating villages for whom informed parental consent was 
obtained were recruited into the study until each of the vaccination groups had at least 30 children.
Study vaccination groups. The study participants were recruited into three groups as outlined in the flow-
chart in Fig. 1. Group 1 and 2 participants were born in PCV7 unvaccinated villages while Group 3 participants 
were born in heavily vaccinated communities following the PCV7 vaccine trials conducted in 20062. Group 2 and 
3 infants received three doses of PCV7 at 2, 3 and 4 months whereas Group 1 infants did not receive PCV7 at this 
age. PCV7 was introduced in the Gambia in August 2009, 11 months after the study was started. Group 1infants 
received at least 1 dose of PCV7 during the national catch-up campaigns. All Group 1 infants were at least 6 
months old when they received the first dose of PCV. Group 2 and Group 3 infants also received additional doses 
of PCV7 following the implementation of PCV7 in The Gambia after 6 months of age. Nasopharyngeal swabs 
were collected within seven days of birth, then biweekly for the first six months and subsequently bi-monthly up 
to one year from all participants.
Nasopharyngeal sampling process. Nasopharyngeal swabs were collected as previously described29 by 
trained field workers. The swab was immediately inoculated into a vial containing 1 mL of chilled skim milk–tryptone–
glucose-glycerol (STGG) transport medium. The vials were kept on ice, transported to the MRCG Laboratories site 
in Fajara and stored at −70 °C within eight hours of collection. Pneumococci were isolated as previously described29.
DNA isolation for 454-pyrosequencing. Nasopharyngeal swabs stored in STGG were thawed on ice 
and gently vortexed for five seconds. DNA was extracted from each swab using the PowerSoil® DNA Isolation 
Kit (MO BIO Laboratories, Carlsbad, CA, USA). 250 µL of the swab solution was transferred to the PowerBead® 
tubes and DNA was extracted following manufacture’s protocol. DNA was eluted in 100 µL of the kit elution buffer 
and immediately stored at −20 °C. DNA extractions were carried out in batches of 24 including one extraction 
control to which 250 µL of sterile DNAse free water was added instead.
16S rDNA sequencing. The V1-V3 region of the 16S rRNA gene were amplified using primers 
5′-AGAGTTTGATCCTGGCTCAG-3′ and 5′-ATTACCGCGGCTGCTGG-3′ as previously described44, 45. The 
primers contained an adapter sequence and unique barcodes. The positive controls for all runs were purified. 
Anaerotruncus colhominis DNA, reagent controls and non-template controls were set up for each PCR run. 
Following amplification and purification, the amplicons were pooled at equimolar concentrations and sequenced 
on the 454 GS FLX Titanium Sequencing Platform (Roche, USA) as described elsewhere44, 45 at the Genome 
Institute (University of Washington in St. Louis, MO, USA).
Quality control and data processing were performed using in-house pipelines at the Jackson Laboratory. 
Briefly, reads with length <200 bp and/or with more than a single ambiguous base call were discarded. Chimeric 
sequences and reads without the adapter sequences were also removed. Reads from the same samples were binned 
based on barcode and then the barcode, adapter and primer sequences at both terminals were trimmed. Samples 
with read depth less than 500 were discarded based on rarefaction analysis of all the samples. Alignment and tax-
onomic classification (Phylum to Genus) of the reads was carried out with the Ribosomal Database Project Naïve 
Bayesian Classifier using a 0.5 filter.
Data collection. At recruitment, background data including birth weight, birthplace, maternal age, maternal 
parity, ethnicity, sex, and vaccination status of mothers and siblings were collected. Socio-demographic and clin-
ical information about the participants was collected at each visit including antibiotic use, anthropometric meas-
urements, travel history, breastfeeding status, and infections (ear and chest). All data were collected on approved 
study forms and double entered and verified in an OpenClinica Electronic Data Capture system (Waltham, MA, 
USA) with an Access (Microsoft, Seattle, WA, USA) backend.
Analysis. Differences in baseline characteristics of the study participants recruited into the three study groups 
were tested using the Chi square test, Fisher’s exact test or Kruskal-Wallis test where appropriate. A mixed effects 
model was used to compare richness and Shannon α diversity across the study groups. Richness was positively 
skewed and was square root transformed for statistical analysis. Time-invariant risk factors (gender, place of birth, 
number of siblings, maternal age) and time-variant risk factors (age, vaccination period, season, breast feeding, trav-
elling, antibiotic usage and nutritional status based on weight for height) were used as explanatory variables. Age and 
vaccination group were the main exposure risk factors and the remaining explanatory risk factors were considered 
as potential confounders. A random-intercept model was used to handle these two types of explanatory risk factors. 
All explanatory risk factors mentioned above were included in the fixed effects component of the model as well as 
pairwise and triple interaction terms between time, group and period. A backward model selection approach using 
the Wald test was adopted. Explanatory risk factors with a non-significant effect at the 5% significance level were 
discarded. Model residuals and random effects were checked for reliability. Kaplan Meier survival curves were used 
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to compare the rates to first acquisition of pneumococcus and PCV7 serotypes in the three study groups. Statistical 
analyses were performed using STATA/SE 14.1, USA. Microbial community composition, structure and ecology 
analyses were performed using the Phyloseq package46 with R version 3.2.1. To reduce noise, low-occurrence, poorly 
represented OTUs were filtered out i.e. OTUs that did not appear more than once in 10% of the samples. To evaluate 
the effect of PCV7 vaccination group on overall microbial composition, the phylogenetic dis(similarities) among 
communities from the three groups were evaluated by metric multidimensional scaling (MDS)/ Principle compo-
nent analysis (PCoA) on weighted UniFrac distance. Differential abundance of individual OTUs across the vaccina-
tion groups was explored using the DESeq package-extensions in the Phyloseq package.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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